Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Laura Shawver
AddedMar 31, 2024
UpdatedMay 31, 2026
Laura Shawver

Laura Shawver

Board Member, ARS Pharmaceuticals

CrunchbaseLinkedIn

Laura Shawver's Career

ARS Pharmaceuticals
ARS Pharmaceuticals

San Diego, CA, US

Board Member· Board
Relay Therapeutics
Relay Therapeutics

Cambridge, MA, US

Board Member· Board
Cleave Therapeutics
Cleave Therapeutics

San Francisco, CA, US

Board Member· Board
Capstan Therapeutics
Capstan Therapeutics

San Diego, CA, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Laura Shawver's Career

ARS Pharmaceuticals
ARS Pharmaceuticals
Public$75M532015San Diego, CA, US
Board Member· Board

Leadership at ARS Pharmaceuticals

Pratik ShahPratik ShahBoard Member
Richard LowenthalRichard LowenthalCo-Founder & CEO
Peter ThompsonPeter ThompsonBoard Member
Michael KellyMichael KellyBoard Member
Saqib IslamSaqib IslamBoard Member
Sarina TanimotoSarina TanimotoCo-Founder

Similar to ARS Pharmaceuticals

Bryn PharmaBryn PharmaBeverly Hills, CA, USPharmaceuticalsest. 2017Bryn PharmaBeverly Hills, CA, US · est. 2017

Bryn Pharma: Providing easy-to-use, portable nasal epinephrine for anaphylaxis treatment.

Series B · $125.2M5
Amphastar PharmaceuticalsAmphastar PharmaceuticalsRancho Cucamonga, CA, USBiologics, Pharmaceuticalsest. 1996Amphastar PharmaceuticalsRancho Cucamonga, CA, US · est. 1996

Amphastar Pharmaceuticals: A leading US-based specialty pharma company, expert in developing injectable and inhalation products.

Public · $300M1.6k
AktivaxAktivaxAurora, CO, USDrug Deliveryest. 2008AktivaxAurora, CO, US · est. 2008

Aktivax innovates drug delivery tech for emergencies, offering robust auto-injectors with extended shelf life.

Angel · $515.3k7
AdrenaCardAdrenaCardMinneapolis, MN, USMedical Devicesest. 2014AdrenaCardMinneapolis, MN, US · est. 2014

AdrenaCard: Integrating life-saving drugs with user-friendly devices for easy carry.

Angel · $1M5
Relay Therapeutics
Relay Therapeutics
Public$1.2B3272016Cambridge, MA, US
Board Member· Board

Leadership at Relay Therapeutics

Alexis BorisyAlexis BorisyBoard Member
Kanishka PothulaKanishka PothulaBoard Member
Mark MurckoMark MurckoBoard Member
Sanjiv PatelSanjiv PatelCEO
Steve KafkaSteve KafkaBoard Member
Jami RubinJami RubinBoard Member
Cleave Therapeutics
Cleave Therapeutics
Series C$101M302011San Francisco, CA, US
Board Member· Board

Leadership at Cleave Therapeutics

Alfred ScheideggerAlfred ScheideggerBoard Member
Amy BurroughsAmy BurroughsCEO
Peter ThompsonPeter ThompsonBoard Member
Raymond DeshaiesRaymond DeshaiesCo-Founder
Capstan Therapeutics
Capstan Therapeutics
Series A$165M1752021San Diego, CA, US
CEO· C-Suite · Management

Leadership at Capstan Therapeutics

Christian HomsyChristian HomsyCo-Founder
Adrian BotAdrian BotCo-Founder
Athena CountouriotisAthena CountouriotisBoard Member
Haig AghajanianHaig AghajanianCo-Founder

Laura Shawver's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Laura Shawver

Mark C. PaullinMark C. PaullinCEO · Capstan SystemsAllen ProithisAllen ProithisCEO · GenXCommStewart WallachStewart WallachBoard Member · Capstone CompaniesJeffrey J. GuzyJeffrey J. GuzyBoard Member · Leatt